Menu

Image of the Day: Morphing Cells

By removing a single gene, researchers change the developmental fate of tumor cells in mice.  

Mar 27, 2018
The Scientist Staff, The Scientist Staff

Stomach and intestinal cells found in mouse lung tumorsTATA LAB, DUKE UNIVERSITY

Researchers at Duke University School of Medicine have prompted cells normally found in the gastrointestinal tract to grow within lung tumors in mice.

They had analyzed lung cancer data from the Cancer Genome Atlas Research Network, a large consortium of genomes of cancer samples, and found lung cancer cells often lacked a gene called NKX2-1. They knocked it out in healthy mice and then activated the oncogenes SOX2 or KRAS to give them cancer. When the researchers examined the tumors from mice that lacked NKX2-1, they found some tumor cells had developed into gastrointestinal cells, their closest developmental counterpart.  

“Cancer cells will do whatever it takes to survive,” says Purushothama Rao Tata, a cell biologist at Duke University School of Medicine, in a statement. “Upon treatment with chemotherapy, lung cells shut down some of the key cell regulators and pick up the characteristics of other cells in order to gain resistance.”

P.R. Tata el al., “Developmental history provides a roadmap for the emergence of tumor plasticity,” Developmental Cell, doi:10.1016/j.devcel.2018.02.024, 2018.

 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.